Continuous glucose monitoring system (Dexcom G6^MC Dexcom)

Notice Santécom: 126399

Type 1 diabetes (T2DM) is an incurable, demanding and serious disease that can have a significant impact on patients and their quality of life. The management of type 1 diabetes is complex and involves multiple daily challenges (adjusting insulin doses, self-monitoring of glucose levels, etc.).

In recent years, devices such as the Dexcom G6^® mobile (G6) system for continuous glucose monitoring have entered the market and provide new options for the diabetic population.

INESSS assessed the relevance of public coverage of this device. Despite recognizing the therapeutic value of the Dexcom G6^®, the cost-benefit ratio was judged to be too high. INESSS thus does not recommend public coverage of Dexcom G6^® at the price submitted, believing it to not be an equitable and reasonable option.